The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

AN2 Therapeutics , Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on developing treatments for infectious diseases, ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...

For more information about VALID Therapeutics and Araceli Biosciences, please visit https://www.validtx.com and www.aracelibio.com. The traditional drug development pipeline is marred by high failure ...

The Astellas pipeline is split nearly 50/50 ... for the option to license the biotech’s lead gene therapy, which is in early clinical development for frontotemporal dementia, a neurodegenerative ...

LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will p ...